From Yahoo Finance: 2025-05-21 13:30:00

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NVAX) stock with a price target of $10 on May 20. The approval of Nuvaxovid for older and high-risk adults will generate $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025, mitigating near-term risks.

JPMorgan maintains an Underweight rating on Novavax (NVAX) stock despite vaccine approval. The demand for COVID vaccines among older populations remains strong, and the impact of stricter labeling on Nuvaxovid’s potential market may not be significant. The full potential of Novavax’s pipeline is yet to be realized, keeping the analyst’s view neutral.

Novavax, Inc. (NVAX) is a biotechnology company focused on developing and commercializing vaccines worldwide. While NVAX has growth potential, other AI stocks may offer higher returns with limited downside risk. Investors seeking a promising AI stock with 100x upside potential can explore further information in a report.

No promotional or marketing content mentioned in the news article.



Read more at Yahoo Finance: BofA Reiterates Hold Rating on Novavax (NVAX) Stock